CAS: 397864-44-7; Fluticasone Furoate
该化合物是一种具有抗炎特性的合成花生类固醇,主要用于治疗哮喘和过敏鼻炎等呼吸状况,其特点是对甘蓝菌受体的高度亲近性,这提高了其在减少炎情和免疫反应方面的功效;该物质通常通过吸入或鼻喷剂施用,允许有针对性地投送到呼吸系统;Floticasonoone wooate表现出长期的行动,它支持了一次的日常施用;其化学结构包括一个氟化类固醇骨,有助于其威力和稳定性;该化合物一般具有良好的燃烧作用,其副作用可能包括局部刺激,或者在罕见的情况下,与使用花生类人有关的系统效应;作为氟虫酮家族的成员,它通常在功效和安全方面与其他花生类固醇相比,使它成为管理慢性炎症的宝贵选择.
- 英文名称Fluticasone Furoate
- 中文名称糠酸氟替卡松
- IUPAC名称(6S,8S,9R,10S,11S,13S,14S,16R,17R)-6,9-difluoro-17-(((fluoromethyl)thio)carbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-yl furan-2-carboxylate
- 其它别名FLUTICASONE FUROATE; Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-17-((2- furanylcarbonyl)oxy)-11-hydroxy-16-methyl-3-oxo-, S-(fluoromethyl) ester, (6alpha,11beta,16alpha,17alpha)-; Veramyst; (6α,11β,16α,17α)-6,9-Difluoro-17-[(2-furanylcarbonyl)oxy]-11-hydroxy-16-Methyl-3-oxoandrosta-1,4-diene-17-carbothioic Acid S-(FluoroMethyl) Ester; AllerMist; AvaMys
- CAS编号397864-44-7
- MFCD编号:MFCD09954122
- EINECS号:629-894-6
- FDA UNII编号:JS86977WNV
- 分子式:C27H29F3O6S
- 分子量:538.58
- 产品CID: 1409620
- 同类组份化合物CAS948566-12-980474-14-2 (propionate)397864-44-7 (furoate)
- 产品分类医药中间体 → 原料药中间体
物理性质
MSDS等安全信息
- GHS象形图
- GHS符号GHS08 & GHS09;
注释: Health hazard & Environment - 危险类别生殖毒性 类别2
特定目标器官毒性-重复接触 类别2
生殖毒性 类别1B
水生慢性毒性 类别1
水生急性毒性 类别1
水生慢性毒性 类别4 - 警示词Danger(危险)
- 危险描述H361 |怀疑对生育能力或胎儿造成损害.
H373 |长期或反复接触可能损害器官.
H361d |怀疑对胎儿造成损害.
H360 |可能损害生育能力或胎儿.
H410 |对水生生物毒性极大并具有长期持续影响.
H400 |对水生生物毒性极大.
H360Df |可能对胎儿造成损害. 怀疑会影响生育能力.
H413 |可能对水生生物造成长期有害影响. - 防范说明P201-P202-P280-P308+P313-P405-P501
- 安全声明H360 (42.86%)H361 (42.86%)H373 (71.43%)
欧盟法规
ECHA物质C&L通报上下游产品
(6A,11B,16A,17A)-6,9-二氟-11,17-二羟基-16-甲基-3-氧代雄甾-1,4-二烯-17-硫代羧酸 6α,9α-Difluoro-11β,17α-Dihydroxy-16α-Methyl-3-Oxo-Androsta-1,4-Diene-17β-Carbothioic Acid 80473-92-36,9-二氟-11,17-二羟基-16-甲基-3-氧代雄甾-1,4-二烯-17-羧酸 6α,9α-Difluoro-11β,17α-Dihydroxy-16α-Methyl-3-Oxoandrosta-1,4-Diene-17β-Carboxylic Acid 28416-82-2
氟米松 Flumetasone 2135-17-3
合成工艺路线路线简述
- 合成目标产物 Fluticasone Furoate 主要起始原料 6α,9α-Difluoro-17α-(Furan-2-yl)Carbonyloxy-11β-Hydroxy-16α-Methyl-3-Oxoandrosta-1,4-Diene-17β-Carbothioic Acid And Bromofluoromethane
- (文献来源)合成步骤主要原料 6α,9α-Difluoro-17α-(Furan-2-yl)Carbonyloxy-11β-Hydroxy-16α-Methyl-3-Oxoandrosta-1,4-Diene-17β-Carbothioic Acid 和 Bromofluoromethane
在 氨体系中,用 甲醇 作为反应溶剂,化学反应 0.08H,反应生成 糠酸氟替卡松
参考文献:Method For The Production Of Fluoromethyl Esters Of Androstan-17 Beta Carboxylic Acids
标题:Method For The Production Of Fluoromethyl Esters Of Androstan-17 Beta Carboxylic Acids
摘要:本文描述了从保护中间体和/或试剂出发制备单氟甲基有机生物活性化合物的过程,以获得如丙酸氟替卡松和富马酸氟替卡松等化合物,其中使用脱羧试剂xef2和brf3或使用fch2Sh作为试剂.
海关参考信息
- 2901210000-乙烯
2901220000-丙烯
2905122000-异丙醇
2905143000-叔丁醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-8697730-B2
优先权日:2007-10-26
标题 :5-lipoxygenase activating protein (FLAP) inhibitor
发明人：REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON
权利人:REWOLINSKI MELISSA VIRGINIA; SCHAAB KEVIN MURRAY; KING CHRISTOPHER DAVID; STOCK NICHOLAS SIMON; PANMIRA PHARMACEUTICALS LLC
摘要:Described herein are methods for the synthesis of 3-[5-(pyridin-2-ylmethoxy)-3-(2-methyl-2-propylthio)-1-[4-(2-methoxypyridin-5-yl)benzyl]-indol-2-yl]-2,2-dimethyl-propionic acid, pharmaceutically acceptable salts, pharmaceutically acceptable solvates thereof. Also described are pharmaceutical compositions suitable for oral administration to a mammal that include, as well as methods of using such oral pharmaceutical compositions for treating respiratory conditions or diseases, as well as other leukotriene-dependent or leukotriene mediated conditions or diseases.
专利号:CN-109574982-A
优先权日:2019-01-22
标 题 :A kind of method for solid acid catalyzed synthesis of vilanterol intermediate
专利号:EP-1930323-A1
优先权日:2004-03-11
标 题:Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists
专利号:EP-1930323-B1
优先权日:2004-03-11
标 题:Biphenyl compounds useful in the synthesis of muscarinic receptor antagonists
专利号:CN-110423233-A
优先权日:2019-06-13
标题 :Preparation method for catalytic synthesis of vilanterol intermediate by modified graphene
专利号:AU-2007275931-A1
优先权日:2006-07-19
标 题:Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
网址: http://www.novelab.com.cn
电话: 86-22-27409838👤
销售电话:86-22-27409838
邮箱：info@novelab.com.cn
电话: 86-22-27409838👤
📞天津诺维莱博科技有限公司 ⚠️参考联系方式
销售电话:86-22-27409838
邮箱：info@novelab.com.cn
🆔 联系时候可告知是从"百琢研"平台获取的信息.
⚠️ 声明: 该企业未认证、未认领，请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实，百琢研不参与任何交易。企业认领注册入口→
⚠️ 未注册 · 未认证企业
备注: 📌 数据来源说明：本展台内容基于各搜索引擎等公开数据整理，仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议， 请通过页面底部联系方式告知我们，我们会尽快处理。第 1 / 1 页
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Albertson TE, Richards JR, Zeki AA. The combination of fluticasone furoate and vilanterol trifenatate in the management of asthma: clinical trial evidence and experience. Ther Adv Respir Dis. 2016 Feb;10(1):43-56. doi: 10.1177/1753465815619136. Epub 2015 Dec 14. Review. doi: 10.1007/s40265-015-0354-5. Review. Epub 2014 Dec 1. Review.
4: Matera MG, Capuano A, Cazzola M. Fluticasone furoate and vilanterol inhalation powder for the treatment of chronic obstructive pulmonary disease. Expert Rev Respir Med. 2015 Feb;9(1):5-12. doi: 10.1586/17476348.2015.986468. Epub 2014 Dec 6. Review. doi: 10.1007/s40265-014-0269-6. Review. doi: 10.2147/COPD.S32604. eCollection 2014. Review.
7: Bollmeier SG, Prosser TR. Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease. Ann Pharmacother. 2014 Feb;48(2):250-7. doi: 10.1177/1060028013512615. Epub 2013 Nov 19. Review. doi: 10.4103/0022-3859.93260. Review. doi: 10.1517/14656566.2011.600688. Epub 2011 Jul 29. Review. doi: 10.1111/j.1365-2222.2010.03654.x. Epub 2010 Dec 1. Review. Review. doi: 10.1517/14656566.9.15.2707 . Review. Review. Review.
合成参考文献
摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198
摘要:Kwiecień, H. U., Science of Synthesis: Knowledge Updates, (2024) 3, 1.
📝 需求与反馈
尽可能描述清楚需求与问题信息
